OROS® Hydromorphone in chronic pain management: When drug delivery technology matches clinical needs

Minerva Anestesiologica

Volumn 76, Issue 12, 2010, Pages 1072-1084

  Coluzzi, F ^a   Mattia, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drug delivery systems; Hydromorphone; Pain; Pharmacokinetics

Indexed keywords

FENTANYL; HYDROMORPHONE; MORPHINE; NALTREXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE;

AREA UNDER THE CURVE; ASTHENIA; BACKACHE; CANCER PAIN; CHRONIC PAIN; CONFUSION; CONSTIPATION; CONTROLLED DRUG RELEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FOOD DRUG INTERACTION; HEADACHE; HIP OSTEOARTHRITIS; HUMAN; INSOMNIA; KNEE OSTEOARTHRITIS; LIPID DIET; LOW BACK PAIN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OSMOTIC PUMP; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRURITUS; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; HYDROMORPHONE; OSMOTIC PRESSURE; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78651233895     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
2. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112:372-80.
3. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002;288:2880-3.
4. Sabate E. Adherence to long-term therapy: evidence for action. Geneva: World Health Organization; 2003
5. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005; 353:487-97.
6. Valeberg BT, Miaskowski C, Hanestad BR, Bjordal K, Moum T, Rustchen T. Prevalence rates for and predictors of self-reported adherence of oncology outpatients with analgesics. Iin J Pain 2008;24:627-36.
7. Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P et al. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol 2001;19:4275-9.
8. Sale JEM, Gignac M, Hawker G. How "bad" does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis. Arthrit Rheumatism 2006;55:272-8.
9. Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behavioural and educational interventions to improve outcomes. J Manag Care Pharm 2008; 14 (6): S2-S10
10. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
11. Coluzzi F, Mattia C. Chronic non-cancer pain: focus on once-daily tramadol formulations. Ther Clin Risk Manag 2007;3:819-29.
12. Weinstein SM. A new extended release formulation (OROS) of hydromorphone in the mnagement of pain. Ther Clin Risk Manag 2009;5:75-80.
13. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opi 2006;22:1879-92.
14. Coluzzi F, Mattia C. Osmotic-Controlled Release Oral Delivery System (OROS® technology) in chronic pain management. Frontiers in Drug Design & Discovery 2009;4:247-72.
15. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987-91
16. Dong L, Shafi K, Wong P, and Wan J. L-OROS SOFTCAPTM for controlled release of non-acqueous liquid formulations. Drug Delivery Technol 2002;2:1-5.
17. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 2002;97:827-36.
18. Angst MS, Drover DR, Lotsch J, Ramaswamy B, Naidu S, Wada DR et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001;94:63-73.
19. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981;21:152-6.
20. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic investigation of dose proportionality with a 24-hour controller-release formulation of hydromorphone. BMC Clinical Pharmacology 2007;7:3.
21. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clinical Pharmacology 2007;7:2.
22. Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin 2008;24:297-305.
23. FDA asks Purdue Pharma to withdraw Palladone. FDA Consum 2005;39:7.
24. Murray S, Wooltorton E. Alcohol-associated rapid release of a long-acting opioid. JAMC 2005;173:756.
25. Quigley C. Hydromorphone for acute and chronic pain. The Cochrane Library 2005;2:1-31.
26. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr, Dornseif BE et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23:355-68.
27. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose conversion and titration study. Int J Clin Pract 2007;61:1671-6.
28. Wallace M, Skowronski R, Khanna S, Tudor J, Thipphawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin 2007;23:P1-P9.
29. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Inter Medical Research 2008; 36:343-52.
30. Hale M, Tudor IC, Khanna S, Thipphawong J. Efficacy and Tolerability of Once-Daily OROS® Hydromorphone and Twice-Daily Extended-Release Oxycodone in Patients with Chronic, Moderate to Severe Osteoarthritis Pain: Results of a 6-Week, Randomized, Open-Label, Noninferiority Analysis. Clin Therap 2007;29:874-88.
31. Hanna M, Thipphawong J. A randomized, double-blind comparison of OROS® hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care 2008;7:17.
32. Wallace M, Moulin DE, Rauck RL, Khanna S, Tudor IC, Skowronski R, Thipphawong J. Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. J Opioid Manag 2009;5:97-105.
33. Hanna M, Tuca A, Thippawong J. An open-label, 1-year extension study of the long-term safety and efficacy of oncedaily OROS® hydromorphone in patients with chronic cancer pain. BMC Palliative Care 2009;8:14.
34. Bass DM, Prevo M, Waxman DS. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS®). Drug Safety 2002;25:1021-33.
35. Turgeon J, Groning R, Sathyan G, Thippawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv 2010;7:137-44.
36. Lussier D, Richarz U, Finco G. Use of hydromorphone, with particular reference to the OROS formulation, in the elderly. Drugs Aging 2010;27:327-35.
37. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs 2009;18:255-63.
38. Shram M, Romach M, Sellers E, Thipphawong J. Assessing the abuse potential of an oral osmotic-controlled extended release (OROS) hydromorphone compared to immediate release hydromorphone. J Pain 2009;10:S45-S45.
39. Ward A, Bozkaya D, Fleischmann J, Dubois D, Sabatowski R, Caro JJ. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Curr Med Res Opin 2007;23:2333-45.